 NEW YORK, Feb. 10, 2021 GLOBE NEWSWIRE -- Applied Therapeutics, Inc. NASDAQ: APLT the Company, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 3,000,000 shares of its common stock, par value 0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock. 